{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:41:23Z","timestamp":1770896483967,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.ymgme.2018.04.013","type":"journal-article","created":{"date-parts":[[2018,4,30]],"date-time":"2018-04-30T05:56:35Z","timestamp":1525067795000},"page":"216-227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy of Idursulfase therapy in patients with Mucopolysaccharidosis type II who initiated enzyme replacement therapy in adult age. A systematic review of the literature"],"prefix":"10.1016","volume":"124","author":[{"given":"J.","family":"P\u00e9rez-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Molt\u00f3-Abad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Mu\u00f1oz-Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Morales-Conejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Ceberio-Hualde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"del Toro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2018.04.013_bb0005","series-title":"GeneReviews(R). Seattle (WA)","author":"Mucopolysaccharidosis","year":"2015"},{"key":"10.1016\/j.ymgme.2018.04.013_bb0010","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1042\/bj2710075","article-title":"Human liver iduronate-2-sulphatase. Purification, characterization and catalytic properties","volume":"271","author":"Bielicki","year":"1990","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0015","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1101\/gr.5.1.71","article-title":"130 kb of DNA sequence reveals two new genes and a regional duplication distal to the human iduronate-2-sulfate sulfatase locus","volume":"5","author":"Timms","year":"1995","journal-title":"Genome Res."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0020","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s004390050641","article-title":"Incidence of the mucopolysaccharidoses in Northern Ireland","volume":"101","author":"Nelson","year":"1997","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0025","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s004399900075","article-title":"The frequency of lysosomal storage diseases in The Netherlands","volume":"105","author":"Poorthuis","year":"1999","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0030","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s10545-005-0112-z","article-title":"Cumulative incidence rates of the mucopolysaccharidoses in Germany","volume":"28","author":"Baehner","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0035","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1002\/ajmg.a.33589","article-title":"A mother and daughter with the p.R443X mutation of mucopolysaccharidosis type II: genotype and phenotype analysis","volume":"152A","author":"Sohn","year":"2010","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.ymgme.2018.04.013_bb0040","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1750-1172-6-72","article-title":"Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease","volume":"6","author":"Scarpa","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0045","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1525-1470.1998.tb01367.x","article-title":"Pebbling of the skin: a marker of Hunter's syndrome","volume":"15","author":"Thappa","year":"1998","journal-title":"Pediatr. Dermatol."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0050","doi-asserted-by":"crossref","first-page":"e377","DOI":"10.1542\/peds.2007-1350","article-title":"Recognition and diagnosis of mucopolysaccharidosis II (hunter syndrome)","volume":"121","author":"Martin","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2018.04.013_bb0055","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","article-title":"Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy","volume":"167","author":"Wraith","year":"2008","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0060","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/cge.12927","article-title":"Genotype-phenotype correlation in 44 Czech, Slovak, Croatian and Serbian patients with mucopolysaccharidosis type II","volume":"91","author":"Dvorakova","year":"2017","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0065","article-title":"Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)","volume":"2","author":"da Silva","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0070","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0075","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/GIM.0b013e3181fea459","article-title":"Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0080","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/GIM.0b013e318206786f","article-title":"Idursulfase treatment of hunter syndrome in children younger than 6 years: results from the hunter outcome survey","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0085","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ymgme.2013.03.001","article-title":"The effect of idursulfase on growth in patients with hunter syndrome: data from the hunter outcome survey (HOS)","volume":"109","author":"Jones","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0090","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10545-017-0075-x","article-title":"Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the hunter outcome survey (HOS)","volume":"40","author":"Burton","year":"2017","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0095","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13023-015-0265-2","article-title":"Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome)","volume":"10","author":"Pano","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0100","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ymgme.2009.08.006","article-title":"Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II)","volume":"99","author":"Okuyama","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0105","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/1756-0500-7-264","article-title":"The clinical case report: a review of its merits and limitations","volume":"7","author":"Nissen","year":"2014","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.ymgme.2018.04.013_bb0110","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ymgme.2017.04.004","article-title":"Efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age. A systematic review and meta-analysis","volume":"121","author":"Perez-Lopez","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0115","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0120","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.ymgme.2018.04.013_bb0125","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ymgme.2006.09.001","article-title":"A phase I\/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (hunter syndrome)","volume":"90","author":"Muenzer","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0130","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13023-014-0129-1","article-title":"Clinical efficacy of enzyme replacement therapy in paediatric hunter patients, an independent study of 3.5 years","volume":"9","author":"Tomanin","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0135","first-page":"65","article-title":"Enzymatic replacement therapy for hunter disease: up to 9 years experience with 17 patients","volume":"3","author":"Parini","year":"2015","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0140","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.medcli.2015.06.015","article-title":"Clinical response to long term enzyme replacement treatment in children, adolescent and adult patients with hunter syndrome","volume":"145","author":"Dalmau Serra","year":"2015","journal-title":"Med. Clin. (Barc.)"},{"key":"10.1016\/j.ymgme.2018.04.013_bb0145","first-page":"57","article-title":"Three adult siblings with Mucopolysaccharidosis type II (hunter syndrome): a report on clinical heterogeneity and 12 months of therapy with Idursulfase","volume":"1","author":"Tchan","year":"2011","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0150","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s10545-014-9686-7","article-title":"Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series","volume":"37","author":"Lampe","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0155","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cca.2013.04.022","article-title":"Idursulfase enzyme replacement therapy in an adult patient with severe Hunter syndrome having a novel mutation of iduronate-2-sulfatase gene","volume":"423","author":"Christianto","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2018.04.013_bb0160","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13023-015-0259-0","article-title":"Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study","volume":"10","author":"Guffon","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0165","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s10897-014-9791-7","article-title":"Health-related quality of life in patients with MPS II","volume":"24","author":"Needham","year":"2015","journal-title":"J. Genet. Couns."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0170","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/gim.2017.30","article-title":"Treatment of mucopolysaccharidosis type II (Hunter syndrome): results from a systematic evidence review","volume":"19","author":"Bradley","year":"2017","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0175","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ymgme.2018.01.002","volume":"123","author":"Sampayo-Cordero","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0180","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13023-017-0712-3","article-title":"Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)","volume":"12","author":"Muenzer","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0185","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-209359","article-title":"Hunter syndrome with its typical heart: a close mimic to rheumatic heart","volume":"2015","author":"Madireddi","year":"2015","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0190","first-page":"e42","article-title":"Early response to idursulfase in a 31-year old male patient with Hunter syndrome","volume":"211","author":"Perez-Calvo","year":"2011","journal-title":"Rev. Clin. Esp."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0195","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ymgme.2011.02.018","article-title":"Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS)","volume":"103","author":"Burton","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0200","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ymgme.2013.08.002","article-title":"The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase","volume":"110","author":"Barbier","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.04.013_bb0205","first-page":"2","article-title":"Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients","volume":"12","author":"Giugliani","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2018.04.013_bb9999","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218301288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218301288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:21:57Z","timestamp":1761088917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719218301288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S1096719218301288"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2018.04.013","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Idursulfase therapy in patients with Mucopolysaccharidosis type II who initiated enzyme replacement therapy in adult age. A systematic review of the literature","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2018.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}